# Mesenchymal Stem Cells to Treat Type 2 Diabetes

Study · id `cardio:ct-nct02302599` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02302599](<https://clinicaltrials.gov/study/NCT02302599>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02302599

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT02302599. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (actual); primary completion 2020-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT02302599, source copy `cardio:ctgov-nct02302599-2021-02-03`, retrieved 2026-10-26)
- Started: 2013-01 (actual) (ClinicalTrials.gov record NCT02302599, source copy `cardio:ctgov-nct02302599-2021-02-03`, retrieved 2026-10-26)
- Primary completion: 2020-12 (actual) (ClinicalTrials.gov record NCT02302599, source copy `cardio:ctgov-nct02302599-2021-02-03`, retrieved 2026-10-26)
- Completion: 2020-12 (actual) (ClinicalTrials.gov record NCT02302599, source copy `cardio:ctgov-nct02302599-2021-02-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02302599, source copy `cardio:ctgov-nct02302599-2021-02-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02302599-2021-02-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Mesenchymal Stem Cells to Treat Type 2 Diabetes
- Acronym: UC-MSCs
- Condition: Type 2 Diabetes
- Condition: Mesenchymal Stem Cells
- Intervention (Biological): Umbilical cord mesenchymal stem cells
- Intervention (Biological): Controlled suspension liquid
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial (`cardio:pubmed-35505375`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 99f1bc57cfa9e8e3e38bd30d805194780a61180a8ed10217dd1659efde4312a8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
